Ricardo  Dolmetsch net worth and biography

Ricardo Dolmetsch Biography and Net Worth

Insider of uniQure
Dr. Ricardo Dolmetsch joined uniQure as President, Research & Development in September 2020. He is responsible for uniQure’s gene therapy research activities, as well as nonclinical development, process development, analytical development and vector development.

Dr. Dolmetsch joins uniQure from Novartis Institutes for Biomedical Research (NIBR), the research arm of Novartis AG (NYSE: NVS), where he served as the Global Head of Neuroscience since 2013. He has led the development of treatments for neurodegenerative and neuropsychiatric diseases, including rare genetically defined disorders. During his tenure, Dr. Dolmetsch played an instrumental role in Novartis’ acquisition of AveXis in 2018 and the successful approval of Zolgensma, a commercial gene therapy for patients with spinal muscular atrophy Type 1. Prior to NIBR, Dr. Dolmetsch was a Professor at Stanford Medical School and a Senior Director at the Allen Institute for Brain Science in Seattle, Washington.

He obtained his bachelor’s degree with honors from Brown University, earned his Ph.D. in neuroscience from Stanford University and conducted his postdoctoral training at Harvard University Medical School and Children’s Hospital Boston.

What is Ricardo Dolmetsch's net worth?

The estimated net worth of Ricardo Dolmetsch is at least $2.77 million as of September 18th, 2023. Dr. Dolmetsch owns 163,404 shares of uniQure stock worth more than $2,774,600 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Dolmetsch may own. Learn More about Ricardo Dolmetsch's net worth.

How do I contact Ricardo Dolmetsch?

The corporate mailing address for Dr. Dolmetsch and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Ricardo Dolmetsch's contact information.

Has Ricardo Dolmetsch been buying or selling shares of uniQure?

Ricardo Dolmetsch has not been actively trading shares of uniQure within the last three months. Most recently, Ricardo Dolmetsch sold 5,841 shares of the business's stock in a transaction on Monday, September 18th. The shares were sold at an average price of $7.46, for a transaction totalling $43,573.86. Following the completion of the sale, the insider now directly owns 163,404 shares of the company's stock, valued at $1,218,993.84. Learn More on Ricardo Dolmetsch's trading history.

Who are uniQure's active insiders?

uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP). Learn More on uniQure's active insiders.

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 8 times. They sold a total of 66,928 shares worth more than $421,017.91. The most recent insider tranaction occured on December, 9th when CEO Matthew C Kapusta sold 3,418 shares worth more than $26,079.34. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.

Information on this page was last updated on 12/9/2024.

Ricardo Dolmetsch Insider Trading History at uniQure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2023Sell5,841$7.46$43,573.86163,404View SEC Filing Icon  
3/7/2023Sell837$21.04$17,610.48169,245View SEC Filing Icon  
12/9/2022Sell2,219$22.30$49,483.70127,406View SEC Filing Icon  
2/28/2022Sell1,484$16.68$24,753.12View SEC Filing Icon  
9/16/2021Sell8,603$37.10$319,171.3069,126View SEC Filing Icon  
See Full Table

Ricardo Dolmetsch Buying and Selling Activity at uniQure

This chart shows Ricardo Dolmetsch's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

uniQure Company Overview

uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $16.98
Low: $15.35
High: $17.58

50 Day Range

MA: $8.13
Low: $5.56
High: $17.40

2 Week Range

Now: $16.98
Low: $3.73
High: $17.71

Volume

2,053,596 shs

Average Volume

1,659,723 shs

Market Capitalization

$827.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89